ACHN 2017 Annual Report

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 22, 2018. ACHILLION PHARMACEUTICALS, INC. By: / S / M ILIND S. D ESHPANDE Milind S. Deshpande Chief Executive Officer Pursuant to the requirements of the Securities Exchange Act of 1934, the Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. Signature Title Date / S / M ILIND S. D ESHPANDE Milind S. Deshpande Chief Executive Officer and Director (Principal executive officer) February 22, 2018 / S / M ARY K AY F ENTON Mary Kay Fenton Executive Vice President and Chief Financial Officer (Principal financial and accounting officer) February 22, 2018 / S / D AVID S CHEER David Scheer Chairman of the Board February 22, 2018 / S / J ASON F ISHERMAN , M.D. Jason Fisherman, M.D. Director February 22, 2018 / S / G ARY E. F RASHIER Gary E. Frashier Director February 22, 2018 / S / K URT G RAVES Kurt Graves Director February 22, 2018 / S / M ICHAEL D. K ISHBAUCH Michael D. Kishbauch Director February 22, 2018 / S / R OBERT V AN N OSTRAND Robert Van Nostrand Director February 22, 2018 / S / F RANK V ERWIEL Frank Verwiel Director February 22, 2018 / S / N ICOLE V ITULLO Nicole Vitullo Director February 22, 2018 101